Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + paclitaxel vs carboplatin + pegylated liposomal doxorubicin in recurrent ovarian cancer
2004-002399-40Phase 3Terminated
- Sponsor
- Rigshospitalet
- Start
- Mar 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in ovarian cancer (OC) comparing Carboplatin + paclitaxel with Carboplatin + pegylated liposomal doxorubicin (2 arms). Primary endpoint: Primary end-point. Started Mar 2005; status: terminated.
02
Drugs
carboplatinpaclitaxeldoxorubicin
03
Conditions
ovarian cancer (OC)
Beyond the preview
Go deeper on 2004-002399-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002399-40.